Anticoagulant drugs: An update

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 4, 2004, Pages 511-522

  Kwaan, Hau C ^a   Samama, Meyer M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University Hospital   (France)

Author keywords

Anticoagulants; Factor Xa inhibitors; Fondaparinux; Heparin; Hirudin; Melagatran; Thrombin inhibitors; Thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ACTIVATED PROTEIN C; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTIVITAMIN K; APTAMER; ARGATROBAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DICOUMAROL; ENOXAPARIN; FONDAPARINUX; HEPARIN; HYPOCHOLESTEROLEMIC AGENT; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDE C2; PEPTIDE DERIVATIVE; RAZAXABAN; RIVAROXABAN; THROMBIN; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; FOOD DRUG INTERACTION; HUMAN; MORBIDITY; MORTALITY; OSTEOPENIA; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBUS;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; HUMANS; THROMBOSIS;

EID: 4043126862     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.4.511     Document Type: Review

References (95)

1. Hirsh J, Hoak J. Management of deep-vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 93, 2212-2245 (1996).
2. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N. Engl. J. Med. 326, 800-806 (1992).
3. Schulman S. Novel anticoagulant agents: introduction. J. Intern. Med. 254, 308-312 (2003).
4. Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein C2 and other inhibitors targeting blood coagulation Factor VIIa/tissue factor. J. Intern. Med. 254, 313-321 (2003).
5. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J. Intern. Med. 254, 322-334 (2003).
6. Hirsh J. Heparin. N. Engl. J. Med. 324, 1565-1574 (1991).
7. Hirsh J. Oral anticoagulant drugs. N. Engl. J. Med. 324, 1865-1875 (1991).
8. Hirsh J, Dalen JE, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 114, S445-S469 (1998).
9. Hirsh J, Raschke R, Warkentin TE et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 108, S258-S275 (1995).
10. Palareti G, Leali N. Bleeding complications of oral anticoagulant treatment: inception-cohort, prospective collaborative study (ISCOAT). Lancet 348, 423-428 (1996).
11. Palareti G, Hirsh J, Legnani C et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch. Intern. Med. 28, 470-478 (2000).
12. Koopman MM, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administrated at home. The Tasman Study Group. N. Engl. J. Med. 334, 682-687 (1996).
13. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334, 677-681 (1996).
14. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86, 385-391 (1990).
15. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644-1654 (2003).
16. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339, 1476 (1992).
17. Prandoni P, Lensing AW, Buller HR et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339, 441-445 (1992).
18. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. 100, 269-277 (1996).
19. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight hepatitis compared with unfractionated heparin for treatment of acute deep-venous thrombosis: a meta-analysis of randomized, controlled trials. Ann. Intern. Med. 130, 800-809 (1999).
20. Khorana AA, Sahni A, Aldand OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler. Thromb. Vasc. Biol. 23, 2110-2115 (2003).
21. McLean J. The thromboplastic action of cephalin. Am. J. Physiol. 41, 250-257 (1916).
22. Howell WH, Holt E. Two new factors in blood coagulation - heparin and proantithrombin. Am. J. Physiol. 47, 328-341 (1918).
23. Link KP. The anticoagulant from spoiled sweet-clover hay. Harvey Lectures 39, 152-216 (1943).
24. Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. J. Biol. Chem. 278, 50819-50832 (2003).
25. Mann KG. Thrombin formation. Chest 124(Suppl. 3), S4-S10 (2003).
26. Morrissey JH. Tissue factor in at the start and the finish? J. Thromb. Haemost. 1, 878-880 (2003).
27. Butenas S, Mann KG. Blood coagulation. Biochemistry 67, 3-12 (2002).
28. Broze GJ. Tissue factor pathway inhibitor. Thromb. Haemost. 74, 90-93 (1995).
29. Sajadi S, Ezekowitz MD, Dhond A, Netrebko P. Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News Perspect. 16, 363-369 (2003).
30. Lee AY, Vlasuk GP. Recombinant nematode anticoagulant protein C2 and other inhibitors targeting blood coagulation Factor VIIa/tissue factor. J. Intern. Med. 254, 312-321 (2003).
31. Rusconi CP, Scardino E, Layzer J et al. RNA aptamers as reversible antagonists of coagulation Factor IXa. Nature 419, 90-94 (2002).
32. Esmon CT, Ding W, Yasuhiro K et al. The protein C pathway: new insights. Thromb. Haemost. 78, 70-74 (1997).
33. Bernard GR, Vincent JL, Laterre PF et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
34. Griffin JH, Zlokovic B, Fernandez JA. Activated protein C: potential therapy for severe sepsis, thrombosis and stroke. Semin. Hematol. 39, 197-205 (2002).
35. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb. Res. 106, 275-284 (2002).
36. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105, 1004-1011 (2002).
37. Mustard JF. The relationship between the structure of a thrombus or a hemostatic plug and the mechanisms involved in its formation. Thromb. Diath. Haemorrha. 28(Suppl.), 57-64 (1968).
38. Rosenberg RD, Aird WC. Vascular bed specific hemostasis and hypercoagulable state. N. Engl. J. Med. 340, 1555-1564 (1999).
39. Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 119, S8-S21 (2001).
40. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119, S64-S94 (2001).
41. Hirsh J, Bates SM. The emerging role of low-molecular-weight heparin in cardiovascular medicine. Prog. Cardiovasc. Dis. 42, 235-246 (2000).
42. Weitz JI. Low-molecular-weight hepatitis. N. Engl. J. Med. 337, 688-698 (1997).
43. Choay J, Petitou M, Lormeau JC et al. Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-Factor Xa activity. Biochem. Biophys. Res. Comm. 116, 492-499 (1983).
44. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res. 109, 1-11 (2003).
45. Olson ST, Björk I, Sheffer R et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 267, 12528-12538 (1992).
46. Walenga JM, Jeske WP, Samama MM et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin. Investig. Drugs 11(3), 397-407 (2002).
47. Walenga JM, Petitou M, Lormeau JC et al. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb. Res. 46, 187-198 (1987).
48. Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of Factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb. Haemost. 76, 5-8 (1996).
49. Hemker HC, Choay J, Beguin S. Free Factor Xa is on the main pathway of thrombin generation in dotting plasma. Biochem. Biophys. Acta 992, 409-411 (1989).
50. Herault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect Factor Xa inhibitors on free and clot-bound prothrombinase. J. Pharmacol. Exp. Ther. 283, 16-22 (1997).
51. Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet. 41(Suppl. 2), 1-9 (2002).
52. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359, 1715-1720 (2002).
53. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359, 1721-1726 (2002).
54. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345, 1305-1310 (2001).
55. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 345, 1298-1304 (2001).
56. Elalamy I, Lecrubier C, Potevin F et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb. Haemost. 74, 1384-1385 (1995).
57. Van Amsterdam R, Vogel G, Visser A et al. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vitro residence time. Arter. Thromb. Vasc. Biol. 15, 495-503 (1995).
58. Herbert JM, Herault JP, Bernat A et al. Biochemical and pharmacological properties of SANORG 32701. Comparison with the 'synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin. Circ. Res. 79, 590-600 (1996).
59. PERSIST Investigators. A novel long-acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep-vein thrombosis. A Phase II evaluation. Blood 100, 301 (2002).
60. Prasa D, Svendsen L, Sturzebecher J. Inhibition of thrombin generation in plasma by inhibitors of Factor Xa. Thromb. Haemost. 78, 1215-1220 (1997).
61. Kaiser B, Jeske W, Walenga JM, Fareed J. Inactivation of Factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coag. Fibrinolysis 10, 495-501 (1999).
62. Tobu M, Iqbal O, Ma Q et al. Global anticoagulant effects of a synthetic anti-Factor Xa inhibitor (DX-9065a): implications for interventional use. Clin. Appl. Thromb. Hemost. 9, 1-17 (2003).
63. Haycraft JB. The action of a secretion obtained from the medicinal leech on the coagulation of the blood. Proc. R. Soc. Lond. 36, 478-487 (1884).
64. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann. Pharmacother. 26, 1535-1540 (1992).
65. Stone SR, Hofsteenge J. Kinetics of inhibition of thrombin by hirudin. Biochemistry 25, 4622-4628 (1986).
66. Rydel TJ, Ravichandran KG, Tulinsky A et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 249, 277-280 (1990).
67. Eichler P, Friesen HJ, Lubenow N et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT and clinical relevance. Blood 96, 2373-2378 (2000).
68. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterisation of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095-7101 (1990).
69. Scatena R. Bivalirudin: a new generation antithrombotic drug. Expert Opin. Investig. Drugs 9(9), 1119-1127 (2000).
70. Chew DP, Bhatt DL, Kimball W et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am. J. Cardiol. 92, 919-923, (2003).
71. Kong DF, Topol EJ, Bittl JA et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 10, 2049-2053 (1999).
72. Eichler P, Lubenow N, Strobel U, Greinacher A. Antibody against lepirudin are polyspecific and recognizes epitopes on bivalirudin. Blood 103, 13-16 (2003).
73. Okamoto S, Hijikata A, Kikumoto R et al. Potent inhibition of thrombin by the newly synthesized arginine derivative number 805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem. Biophys. Res. Commun. 101, 440-446 (1981).
74. Hijikata-Okunomiya A, Okamoto S Wanaka K. Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin III. Thromb. Res. 59, 967-977 (1990).
75. Hijikata-Okunomiya A, Kataoka N. Argatroban inhibits staphylothrombin. J. Thromb. Haemost. 1, 2060-2061 (2003).
76. Hursting MJ, Alford KL, Becker JC et al. Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin. Thromb. Hemost. 23, 503-516 (1997).
77. Fareed J, Lewis BE, Callas DD et al. Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin. Appl. Thromb. Hemost. 5, S45-S55 (1999).
78. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838-1843 (2001).
79. Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann. Pharmacother. 35, 440-451 (2001).
80. Gustafsson D, Nyström JE, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral prodrug H376/95, intestinal absorption properties, biochemical and pharmacodynamic effect. Thromb. Res. 101, 171-118 (2001).
81. Nylander S, Matsson C. Thrombin induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coag. Fibrinol. 14, 1-9 (2003).
82. Sarich TC, Woltz M, Eriksson UG et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J. Am. Coll. Cardiol. 41, 557-564 (2003).
83. Lebrazi J, Elalamy I, Samama MM. In vitro effect of melagatran and lepirudin on clot bound thrombin. Thromb. Res. 110, 249-252 (2003).
84. Gustafsson D, Antonsson T, Bylund R et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor on thrombin and fibrinolytic enzymes. Thromb. Haemost. 79, 110-118 (1998).
85. Eriksson UG, Bredberg U, Gislén K et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur. J. Clin. Pharmacol. 59(1), 35-43 (2003).
86. Eriksson H, Eriksson U, Frison L et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb. Haemost. 81, 358-363 (1999).
87. Eriksson BI, Arfwidsson A-C, Frison L et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb. Haemost. 87, 231-237 (2002).
88. Kelley RF, Refino CJ, O'Connell MP et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 89, 3219-3227 (1997).
89. Taylor FB Jr. Role of tissue factor and Factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 26, 83-91 (1996).
90. Rivera TM, Leone-Bay A, Paton DR et al. Oral delivery of heparin in combination with sodium N-(8-(2-dyfroxybenzoyl) amino) caproate: pharmacological considerations. Pharm. Res. 14, 1830-1834 (1997).
91. Brayden D, Creed E, O'Connell A et al. Heparin absorption across the intestine: effect of sodium N-(8-(2-dyfroxybenzoyl) amino) caproate in rat in situ intestinal instillations and Caco-2 monolayers. Pharm. Res. 14, 1772-1779 (1997).
92. Benedict CR, Ryan J, Wolitzky B et al. Active site-blocked Factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. Clin. Invest. 88, 1760-1765 (1991).
93. Gomi K, Zushi M, Honda G et al. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 75, 1396-1399 (1990).
94. Feuerstein GZ, Toomey JR, Valocik R et al. An inhibitory anti-Factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis. Thromb. Haemost. 82, 1443-1545 (1999).
95. Brady SF, Stauffer KJ, Lumma WC et al. Discovery and development of the novel potent orally-active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analog synthesis on solid support. J. Med. Chem. 41, 401-406 (1998).